Clinical Trial Update: Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications. [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for delayed-release rifaximin in preventing recurrent diverticulitis and diverticular complications; trial phases 2 and 3 have been termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diverticulitis

Drugs mentioned

• rifaximin delayed release (rifaximin)

Snippet

Sponsor: Alfasigma S.p.A. | Conditions: Diverticulitis | Phase 2, Phase 3 | Status: TERMINATED